Contact
searchSearch
HMP Global
Login

Myeloproliferative Neoplasms

Myeloproliferative Neoplasms
Excellence Forum
Leaders in the field sharing authoritative insights and institutional best practices.

Pinkal Desai MD, MPH
Videos
Considering the Impact of Bone Marrow Diseases on the Progression of Myeloid-Related Neoplasms
10/14/2025
Pinkal Desai, MD
At the 2025 Lymphoma, Leukemia & Myeloma Congress, Pinkal Desai MD, MPH, discusses the increased risk of myeloid-related neoplasms for patients with unidentified and untreated bone marrow diseases.
At the 2025 Lymphoma, Leukemia & Myeloma Congress, Pinkal Desai MD, MPH, discusses the increased risk of myeloid-related neoplasms for patients with unidentified and untreated bone marrow diseases.
At the 2025 Lymphoma, Leukemia &...
10/14/2025
Oncology
Claire Harrison, MD
Videos
MAJIC-PV Study Indicates Ruxolitinib Treatment Yields Superior Responses for Patients With Polycythemia Vera
06/21/2023
Claire Harrison, MD
Claire Harrison, MD, presents results from the phase 2 MAGIC-PV trial, which indicate that ruxolitinib treatment yielded superior event-free survival and complete responses vs best available therapy for patients with...
Claire Harrison, MD, presents results from the phase 2 MAGIC-PV trial, which indicate that ruxolitinib treatment yielded superior event-free survival and complete responses vs best available therapy for patients with...
Claire Harrison, MD, presents...
06/21/2023
Oncology
Claire Harrison, MD
Videos
Second-Line Therapy for Patients With Polycythemia Vera: A Review of Data on Ruxolitinib
05/04/2023
Claire Harrison, MD; Jean-Jacques Kiladjian; Alessandro Rambaldi, MD
In the final part of an expert roundtable series, Claire Harrison, MD, leads a panel discussion reviewing data on second-line therapies, particularly ruxolitinib, for patients with polycythemia vera with Jean-Jacques Kiladjian, MD, and...
In the final part of an expert roundtable series, Claire Harrison, MD, leads a panel discussion reviewing data on second-line therapies, particularly ruxolitinib, for patients with polycythemia vera with Jean-Jacques Kiladjian, MD, and...
In the final part of an expert...
05/04/2023
Oncology
Claire Harrison, MD
Videos
How to Determine When First-Line Therapy for Polycythemia Vera is Failing
05/04/2023
Claire Harrison, MD; Jean-Jacques Kiladjian; Alessandro Rambaldi, MD
In part 3 of an expert roundtable series, Claire Harrison, MD, leads a panel discussion on how to determine when first-line polycythemia vera therapy is failing with Jean-Jacques Kiladjian, MD, and Alessandro Rambaldi, MD.
In part 3 of an expert roundtable series, Claire Harrison, MD, leads a panel discussion on how to determine when first-line polycythemia vera therapy is failing with Jean-Jacques Kiladjian, MD, and Alessandro Rambaldi, MD.
In part 3 of an expert...
05/04/2023
Oncology
Claire Harrison, MD
Videos
Aims of Treatment and Choice of First-Line Therapy for Patients With Polycythemia Vera
05/04/2023
Claire Harrison, MD; Jean-Jacques Kiladjian; Alessandro Rambaldi, MD
In part 2 of an expert roundtable series, Claire Harrison, MD, leads a discussion on the aims of treatment and choice of first-line therapy for patients with polycythemia vera with Jean-Jacques Kiladjian, MD, and Alessandro Rambaldi, MD.
In part 2 of an expert roundtable series, Claire Harrison, MD, leads a discussion on the aims of treatment and choice of first-line therapy for patients with polycythemia vera with Jean-Jacques Kiladjian, MD, and Alessandro Rambaldi, MD.
In part 2 of an expert...
05/04/2023
Oncology
Claire Harrison, MD
Videos
Diagnostics and Risk Stratification for Patients With Polycythemia Vera
04/19/2023
Claire Harrison, MD; Jean-Jacques Kiladjian; Alessandro Rambaldi, MD
Claire Harrison, MD, discusses the latest updates in diagnostics and risk stratification of polycythemia vera with Jean-Jacques Kiladjian, MD, and Alessandro Rambaldi, MD.
Claire Harrison, MD, discusses the latest updates in diagnostics and risk stratification of polycythemia vera with Jean-Jacques Kiladjian, MD, and Alessandro Rambaldi, MD.
Claire Harrison, MD, discusses...
04/19/2023
Oncology
Dr Mesa
Videos
Ruben Mesa, MD, Discusses Momelotinib in Patients With Myelofibrosis
03/16/2022
Ruben A. Mesa, MD, FACP
Ruben Mesa, MD, discusses the phase 3 MOMENTUM trial evaluating momelotinib in patients with MF who are symptomatic and anemic.
Ruben Mesa, MD, discusses the phase 3 MOMENTUM trial evaluating momelotinib in patients with MF who are symptomatic and anemic.
Ruben Mesa, MD, discusses the...
03/16/2022
Oncology
Interview
Inflammation Makes for a Logical Therapeutic Target in MPNs
03/15/2018
Angela Fleischman, MD, discusses the role of inflammation in MPN transition to leukemia.
Angela Fleischman, MD, discusses the role of inflammation in MPN transition to leukemia.
Angela Fleischman, MD, discusses...
03/15/2018
Oncology
Videos
Key Insights: MPN and MDS
02/27/2018
Recent advances in understanding the biology of MPN have spurred significant discoveries that have the potential to change the paradigm of how MPN and MDS are diagnosed and treated.
Recent advances in understanding the biology of MPN have spurred significant discoveries that have the potential to change the paradigm of how MPN and MDS are diagnosed and treated.
Recent advances in understanding...
02/27/2018
Oncology
Videos
Best of the Day: from the 2016 Annual Hematology Meeting - CML & MPN
02/27/2018
Drs Joseph R Mikhael and Ruben A Mesa analyze and discuss pertinent clinical studies and late breaking updates pertaining the care of patients with chronic myelogenous leukemia and myeloproliferative neoplasms.
Drs Joseph R Mikhael and Ruben A Mesa analyze and discuss pertinent clinical studies and late breaking updates pertaining the care of patients with chronic myelogenous leukemia and myeloproliferative neoplasms.
Drs Joseph R Mikhael and Ruben A...
02/27/2018
Oncology

Recent News

FDA Approval
FDA Approves Amivantamab and Hyaluronidase for Previously Treated Head and Neck Squamous Cell Carcinoma
11/06/2026
Stephanie Holland
Results from the phase 1b/2 OrigAMI-4 trial supported FDA accelerated approval of subcutaneous amivantamab and hyaluronidase for previously treated recurrent or metastatic head and neck squamous cell carcinoma, introducing a dual...
Results from the phase 1b/2 OrigAMI-4 trial supported FDA accelerated approval of subcutaneous amivantamab and hyaluronidase for previously treated recurrent or metastatic head and neck squamous cell carcinoma, introducing a dual...
Results from the phase 1b/2...
11/06/2026
Oncology
News
Varegacestat Advances Toward European Approval for Desmoid Tumors Following RINGSIDE Survival Benefit
11/05/2026
Emily Estrada
Based on results from the phase 3 RINGSIDE trial, the European Medicines Agency has validated the marketing authorization application for varegacestat in adults with desmoid tumors, following significant improvements in progression-free...
Based on results from the phase 3 RINGSIDE trial, the European Medicines Agency has validated the marketing authorization application for varegacestat in adults with desmoid tumors, following significant improvements in progression-free...
Based on results from the phase...
11/05/2026
Oncology
News
Lirafugratinib Receives NCCN Category 2A Recommendation Following FDA Approval in FGFR2-Altered Cholangiocarcinoma
11/05/2026
Emily Estrada
Following FDA approval supported by the phase 1/2 ReFocus trial, lirafugratinib has been added to the NCCN Guidelines as a Category 2A preferred subsequent-line treatment option for patients with cholangiocarcinoma harboring FGFR2 fusions or...
Following FDA approval supported by the phase 1/2 ReFocus trial, lirafugratinib has been added to the NCCN Guidelines as a Category 2A preferred subsequent-line treatment option for patients with cholangiocarcinoma harboring FGFR2 fusions or...
Following FDA approval supported...
11/05/2026
Oncology
News
Pumitamig Plus Chemotherapy Shows Antitumor Activity Regardless of Brain Metastasis Status
11/04/2026
Emily Estrada
Results from two phase 2 trials demonstrated encouraging intracranial responses with pumitamig plus chemotherapy in patients with small cell lung cancer and triple-negative breast cancer with brain metastases, supporting further investigation...
Results from two phase 2 trials demonstrated encouraging intracranial responses with pumitamig plus chemotherapy in patients with small cell lung cancer and triple-negative breast cancer with brain metastases, supporting further investigation...
Results from two phase 2 trials...
11/04/2026
Oncology
News
SEZ6-Targeted Antibody-Drug Conjugate ABBV-706 Demonstrates Promising Antitumor Activity in Relapsed or Refractory Small Cell Lung Cancer
11/04/2026
Emily Estrada
Updated phase 1 results demonstrated promising antitumor activity with the SEZ6-targeted antibody-drug conjugate ABBV-706 in relapsed or refractory small cell lung cancer, with encouraging response and survival outcomes alongside exploratory...
Updated phase 1 results demonstrated promising antitumor activity with the SEZ6-targeted antibody-drug conjugate ABBV-706 in relapsed or refractory small cell lung cancer, with encouraging response and survival outcomes alongside exploratory...
Updated phase 1 results...
11/04/2026
Oncology
News
Phase 1 Trial Shows 70% Response Rate With SKB500 in Heavily Pretreated Patients With Small Cell Lung Cancer
11/04/2026
Emily Estrada
Updated results from a phase 1 trial demonstrated promising antitumor activity with the B7-H3-directed antibody-drug conjugate SKB500 in heavily pretreated patients with small cell lung cancer, with the lower dose showing more favorable...
Updated results from a phase 1 trial demonstrated promising antitumor activity with the B7-H3-directed antibody-drug conjugate SKB500 in heavily pretreated patients with small cell lung cancer, with the lower dose showing more favorable...
Updated results from a phase 1...
11/04/2026
Oncology
News
Varegacestat Significantly Improves Pain, Physical Function, and Quality of Life in Patients With Desmoid Tumors
11/04/2026
Emily Estrada
Results from RINGSIDE trial demonstrated rapid and sustained improvements in patient-reported pain, desmoid-related symptoms, physical function, and quality of life with varegacestat compared with placebo in patients with progressing desmoid...
Results from RINGSIDE trial demonstrated rapid and sustained improvements in patient-reported pain, desmoid-related symptoms, physical function, and quality of life with varegacestat compared with placebo in patients with progressing desmoid...
Results from RINGSIDE trial...
11/04/2026
Oncology
FDA Alerts
Zanubrutinib Combination Receives FDA Priority Review Following Positive Phase 3 MANGROVE Results
11/04/2026
Stephanie Holland
Results from the phase 3 MANGROVE trial supported FDA Priority Review of zanubrutinib plus rituximab for previously untreated mantle cell lymphoma, following a significant progression-free survival benefit compared with bendamustine plus...
Results from the phase 3 MANGROVE trial supported FDA Priority Review of zanubrutinib plus rituximab for previously untreated mantle cell lymphoma, following a significant progression-free survival benefit compared with bendamustine plus...
Results from the phase 3...
11/04/2026
Oncology
News
Medicare Expands Coverage of Signatera MRD Testing for Hepatocellular Carcinoma Surveillance
11/03/2026
Stephanie Holland
Medicare coverage has been extended to serial Signatera molecular residual disease testing for surveillance of patients with early-stage hepatocellular carcinoma who have no evidence of disease following surgery, supported by real-world...
Medicare coverage has been extended to serial Signatera molecular residual disease testing for surveillance of patients with early-stage hepatocellular carcinoma who have no evidence of disease following surgery, supported by real-world...
Medicare coverage has been...
11/03/2026
Oncology
News
What to Expect at the 2026 NANETS Multidisciplinary NET Medical Symposium
11/02/2026
Janelle Bradley
The 2026 NANETS Multidisciplinary NET Medical Symposium will spotlight emerging research, evolving treatment strategies, and practical insights to advance neuroendocrine tumor care.
The 2026 NANETS Multidisciplinary NET Medical Symposium will spotlight emerging research, evolving treatment strategies, and practical insights to advance neuroendocrine tumor care.
The 2026 NANETS...
11/02/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use